Purpose The fabrication of ready-to-use immediate release tablets via 3D printing provides a powerful tool to on-demand individualization of dosage form. This work aims to adapt a widely used pharmaceutical grade polymer, polyvinylpyrrolidone (PVP), for instant on-demand production of immediate release tablets via FDM 3D printing. Methods Dipyridamole or theophylline loaded filaments were produced via processing a physical mixture of API (10%) and PVP in the presence of plasticizer through hot-melt extrusion (HME). Computer software was utilized to design a caplet-shaped tablet. The surface morphology of the printed tablet was assessed using scanning electron microscopy (SEM). The physical form of the drugs and its integrity following an FDM 3D printing were assessed using x-ray powder diffractometry (XRPD), thermal analysis and HPLC. In vitro drug release studies for all 3D printed tablets were conducted in a USP II dissolution apparatus. Results Bridging 3D printing process with HME in the presence of a thermostable filler, talc, enabled the fabrication of immediate release tablets at temperatures as low as 110°C. The integrity of two model drugs was maintained following HME and FDM 3D printing. XRPD indicated that a portion of the loaded theophylline remained crystalline in the tablet. The fabricated tablets demonstrated excellent mechanical properties, acceptable in-batch variability and an immediate in vitro release pattern.
INTRODUCTION
3D printing established roots in various disciplines from arts and engineering to implants and regenerative medicine (1, 2) . As yet the exploitation of 3D printing for pharmaceutical applications is still at its infancy. However, with the emergence of the first FDA approved 3D printed tablet, Spritam (3), the momentum of this technology is on track to potentially change many means of production for oral dosage forms.
The absence of large array of commercially available API combinations and strengths remains the most frequent problem facing compounding pharmacies today (4) . Traditional tableting methods require multiple processing stages, costly facilities and experienced personnel, thus rendering tablet manufacturing impractical when dose modification for one or small group of patients is required. By contrast, 3D printing, not only circumvent these challenges of conventional tabletting, but also offers means of fabricating medicines at the point of dispensing (5) . Amongst the different explored 3D printing technologies, fused deposition modelling (FDM) shows significant promise in low-cost dose fabrication (6) . This stems up from the fact that FDM printers are available today at low cost and capable of producing 3D objects with a high accuracy and without post-printing steps (7) .
Fused deposition modelling (FDM) involves passing a filament based on thermoplastic polymers through a hot nozzle, where temperature is eleveted above its glass transition temperature (Tg). The extruded material is deposited layer by layer to form an object, where solidification occurs in less than a second. The potential of FDM 3D printers has been explored in the incorporation of different API molecules through their loading into commercially available PVA filaments (7) (8) (9) . These previous attempts, however, displayed several limitations such as the use of non-pharmaceutical grade ingredients and limited drug loading (9, 10) . Previous reports suggested the need for using high temperatures [220°C (8) , 210°C (9) and 250°C (7)] when PVA based dosage forms were fabricated using FDM 3D printers. Moreover, several examples of PLA printed stuctures employed a temperature range of 180-210°C (11) (12) (13) .
Despite the advancement in FDM 3D printing, the array of polymers currently exploited for FDM 3D printing remain limited. The employed polymers for FDM printing in oral drug delivery were restricted to the extended release polymers such as PVA (6) (7) (8) and PLA (14) . The major limitation of FDM 3D printing renders it unsuitable for the production of immediate release tablets, which count for approximately 70% of all oral dosage forms (15, 16) . In rare example, our group reported the fabrication of immediate release tablet based on positively charged methacylic polymers (17) . Polyvinylpyrrolidone (PVP) is known to have a growing pharmaceutical applications with solubility enhancing abilities (18) (19) (20) . It is of great interest to adapt this water soluble polymer to fabricate tablet with immediate release profile. In this current work, we explored the feasibility of employing FDM 3D printing to encompass this important polymer in the pharmaceutical field. We have used a temperature in this work, up to the authors knowledge, is the lowest to have been explored in constructing drug delivery dosage forms, hence broadening the spectra of materials that could be used with FDM.
MATERIALS AND METHODS

Materials
Theophylline (melting point 270°C) (21) was purchased from Acros Organics. Polyvinylpyrrolidone (PVP, MW 40,000) and dipyridamole (melting point 165°C) (22) were purchased from Sigma-Aldrich (UK). Talc was ordered from Fluka Analytical (UK). Triethyl citrate was purchased from Sigma-Aldrich (Dorset,UK) and Scotch blue painter's tape 50 mm was supplied by 3 M (Bracknell, UK).
Preparation of Filaments using HME
For the preparation of the API-free filaments a Thermo Scientific HAAKE MiniCTW hot melt extruder (Karlsruhe, Germany) was utilised. An optimised ratio of a powder mixture constituting of the polymer (PVP), plasticizer (TEC), filler (talc) and API (theophylline or dipyridamole) at (50,12.5, 27.5 and 10%wt) respectively, was gradually added to the HME and allowed to mix for 5 min at 100°C to allow homogenous distribution of the molten mass. Afterwards, extrusion took place at 90°C at a torque of 0.4 Nm.
Tablet Design and 3D Printing
Tablets in this study were designed in a caplet shape using an Autodesk ® Building Design Suite Ultimate 2016 (Autodesk, Inc., USA). The templates design was then imported to the 3D printer's software in a stereolithography (.stl) file format. For the printing of tablets, pre-prepared filaments were fed into a commercial FDM 3D printer equipped with 0.4 mm nozzle size and MakerWare software Version 2.4.0.17 (Makerbot Industries, LLC., USA). Tablets were printed using modified settings of the software as described earlier in our previous work (17) .
Thermal Analysis
For modulated temperature differential scanning calorimetry (MTDSC) analysis, a differential scanning calorimeter (DSC) Q2000 (TA Instruments, Elstree, Hertfordshire, UK) with a heating rate of 2°C/min was employed. Each sample was subjected to a heat-cool-heat scan in order to measure and exclude the effect of moisture contents on filament plasticity. A modulated scan was applied using an amplitude of 0.212°C and a period of 40 sec was used, scanning from −70 to 200°C. Analysis was carried out under a purge of nitrogen (50 mL/ min). The data was analysed using a TA 2000 analysis software. TA pin-holed lid and 40 μL aluminium pans were filled with approximately 5 mg sample. All measurements were carried out in triplicates.
For TGA analysis, printed tablets, raw materials as well as extruded filaments were measured using a TGA Q5000 (TA Instruments, Hertfordshire, UK). Samples (10 mg) were added to an aluminium pan without lid. Samples were then heated from 25 to 500°C at a heating rate of 10°C/min. All measurements were carried out in triplicates.
X-ray Powder Diffractometry (XPRD)
A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used to assess the physical form of APIs in PVP, PVP:TEC filament, API-free and API-loaded filaments, and 3D printed tablets. Samples were scanned from 2Theta (2θ) = 5°to 50°using 0.01°step width and a 1 s time count. The divergence slit was 1 mm and the scatter slit 0.6 mm. The wavelength of the X-ray was 0.154 nm using Cu source and a voltage of 30 kV. Filament emission was 10 mA using a scan type coupled with a two theta/theta scintillation counter over 30 min.
Characterisation of the Tablets Properties
Tablets in this study were characterised for; weight variation, drug content, friability, hardness and disintegration time. For determination of weight uniformity, 20 tablets were randomly selected and weighed individually using a digital analytical balance Ohaus ® (Discovery DV215CD). The average weights of the tablets was measured and the percentage deviation from the mean was then determined.
The crushing strength of 10 tablets was measured using a TBH 220 D (Erweka GmbH, Heusenstamm, Germany). The friability of the 3D printed tablets was determined using an Erweka Friability Tester TAR 10 (Erweka GmbH, Heusenstamm, Germany). Twenty tablets were randomly selected, weighed and tested at a rotation of 25 rpm for 4 min. Tablets were then collected, dusted and reweighed. The differences in weight were calculated and displayed as a percentage of the original sample weight.
In order to determine the disintegration time for the 3D printed tablets, an Erweka ZT 220 Disintegration tester (Erweka GmbH, Heusenstamm, Germany) was utilised. Six tablets were randomly selected and individually placed in the 6 cylinders of the basket rack assembly. The tablets in the cylinders were then covered with discs and the basket rack was immersed into a beaker containing 750 mL of 0.1 M HCl at 37 ± 0.5°C. The time required for all tablets to leave the mesh was then visually assessed.
Determination of Drug Content
In order to examine the effect of HME and FDM 3D printing on the integrity of drug, API-loaded filaments and 3D printed tablets were analysed for drug content prior and following HME as well as in the 3D printed tablets. Samples (dipyridamole loaded filaments or tablets) were accurately weighed and placed in a 500 mL of 1:1 water:acetonitrile mixture for 2 h under sonication. The solution were filtered through 0.22 μm Millex-GP syringe filters (Merck Millipore, USA) and prepared for HPLC analysis.
Dipyridamole contents in relevant samples were assessed using an Agilent UV-HPLC 1260 series (Agilent Technologies, Inc., Germany) equipped with XTerra RP 18 column (150 × 4.6 mm, 5 μm particle size) (Waters, Ireland) at temperature 40°C. The mobile phase (60:40 phosphate buffer pH 6.8: acetonitrile) was employed at a flow rate 1 mL/min and dipyridamole was detected at a wavelength of 282 nm. The injection volume was 10 μL with a stop time of 10 min per sample.
For theophylline, the same UV-HPLC system and column were used as detailed above. A mobile phase constituted of 10 mM solution of ammonium acetate buffer, methanol and acetonitrile (86:7:7) was used. Analysis was carried out at a wavelength of 272 nm, temperature of 40°C, flow rate of 1 mL/min, injection volume was 5 μL and a run time of 7 min.
Scanning Electron Microscopy (SEM)
The surface morphology of the filaments and the printed tablets was examined using Quanta-200 SEM microscope at 20 kV. Samples were placed on a metallic stub and gold coated under vacuum using JFC-1200 Fine Coater (Jeol, Tokyo, Japan). Photographs of the tablets were also taken with a Canon EOS-1D Mark IV (Canon Ltd, Japan).
In vitro Drug Release Studies
In vitro drug release studies was investigated using an Erweka DT 600 dissolution tester (USP II). Three tablets were randomly selected and individually placed in the dissolution vessels each containing 900 mL of 0.1 M HCl and stirred at 50 rpm and 37 ± 0.5°C. Four mL aliquots were manually c o l l e c t e d u s i n g 5 m L L e u r -L o k s y r i n g e s a t (0,5,10,15,20,25,30,40,50,60 and 70 min) time intervals and filtered through a Millex-HA 0.45-μm filter. Each aliquot withdrawn was replaced with 4 mL of 0.1 M HCl. The absorbance of the samples were finally measured using a UV spectrophotometer (Bibby Scientific Ltd, UK) at 282 and 272 nm for dipyridamole and theophylline respectively.
Statistical Analysis
One-way ANOVA was employed using SPSS Software (22.0.0.2) to analyse the results. Differences in results above probability level (p > 0.05) was considered not significant whilst; (p < 0.001) were considered very significant and between p = 0.01 and 0.05 were considered significant. Figure 1 illustrates different steps used in the preparation of tablets by combining HME and FDM 3D printing. API, polymer and other filler were physically mixed and processed via HME to produce 1.75 mm filament at 90°C. CAD software was used to produce a caplet-shaped tablet that was printed via a benchtop FDM 3D printer.
RESULTS AND DISCUSSION
PVP is frequently used in HME to enhance the dissolution pattern of poorly soluble molecules (23) (24) (25) (26) (27) . TGA thermographs ( Fig. 2a and b) revealed a significant mass loss from PVP filaments around 100°C due to dehydration of the PVP filaments. A second mass loss was also apparent at 400°C indicating the degradation of PVP. Also the plasticiser, TEC degrades at temperatures >200°C (Fig. 2a and b) . This renders it unsuitable for FDM 3D printing under the recommended printing temperature of 200-220°C, thus highlighting the importance of lowering the temperature during the process of 3D printing to suit a variety of APIs and pharmaceutical excipients. The thermal stability of dipyridamole (28) and theophylline (29) were in agreement with previous reports and both APIs were stable at temperatures <200°C.
When PVP filament (no filler) were used as a feed for 3D printer, it was not possible to fabricate a structure via FDM 3D printing process due to poor flow from the hot nozzle of the printer and the formation of collapsed structure (data not shown). In order to formulate a stable structure and allow rapid solidification of the filament from the hot nozzle of the 3D printer, a thermostable filler, talc (melting points being >1500°C), was added to the composition of the filament. The latter did not degrade at the temperature range utilised in this study (30) and allowed the formation of relatively smooth and rapidly solidified structure. Talc is a commonly used excipient in the pharmaceutical manufacturing of tablets and capsules (31, 32) and has been shown to have less effects on tablet properties when compared to other lubricants (33) . It is not absorbed systematically and therefore referred to as a nontoxic material (34) . Talc was also approved as a food additive in Europe and included in the Database of Inactive Ingredients by the FDA (34) .
DSC thermographs, at the first heat-scan, all displayed a large endothermal event in the range of 50-110°C due to polymer dehydration (Fig. 3) . This might be related to the hygroscopic nature of PVP, where electronegative groups of the carbonyl in pyrrolidone structure are able to from hydrogen bonds with water (35) . Therefore, a modulated heat-scan was utilized to assess this event-complex. In order to assess the impact of water on glass transition temperature (Tg), a heatcool-heat scan was employed. to the plasticising effect of water. On the other hand, the second heat-scan indicated a significantly higher Tg value of 93°C (in comparison to the Tg of first heat-scan, p < 0.05), confirming that moisture has an impact on the plasticity of PVP. Such a plasticizing effect of moisture on PVP was previously reported (36, 37) .
The addition of talc did not show any significant effect on the thermal behaviour of PVP as noted in the first and second heatscans. The addition of dipyridamole and theophylline shifted the Tg of the filament in the second scan from 93 to 73 and 69°C respectively. Such depression in the Tg indicates a plasticizing effect of dipyridamole and theophylline. Similar findings have been reported earlier for other API-PVP blends (38) .
The XRPD patterns of dipyridamole loaded filament and tablets (Fig. 4) showed the absence of peaks at (2θ) = 10. (39) , indicating no crystalline presence in the PVP matrices . XRPD spectra for theophylline alone elucidated diffraction peaks at (2θ) =7, 12, 14 and 24°analogous to previous findings (17, 40) . However, the presence of some peaks at (2θ) =12 and 7°indicated that a percentage of theophylline remained in the crystalline form.
In order to examine the effect of hot melt extrusion and 3D printing on the APIs, drug content analysis in the HME extruded filaments prior to 3D printing as well as in the 3D printed tablets was carried out. As elucidated in Table I , the content of drug was neither affected by HME extrusion nor by 3D printing. Content uniformity was found to be 102.60 ± 0.59 and 100.23 ± 0.09% for dipyridamole and theophylline, respectively, in the extruded filaments. This high drug content was found to remain the same in the 3D printed tablets (101.18 ± 3.91 and 99.56 ± 0.48%) for dipyridamole and theophylline, respectively. In an earlier study, FDM 3D printing at (210°C) was found to thermally degrade more than half the drug load (5-ASA) (9) . Lowering the printing temperature to 110°C against the recommended temperature by the 3D printer manufacturer (230°C) (41) favours its use for various materials, as reflected by the high drug content in this study.
Photographs and SEM images showed that the structure of filament was smooth with few apparent gaps or voids (Figs. 1e and 5a). Fabricated tablets were constructed from overlaid layers of filament with an approximate height of 200 μm. This thickness can be increased to 400 μm or decreased into 100 μm per layer, as required, via adjusting the resolution of the slicing engine of the printer (17) . The potential of utilising FDM 3D printing in modifying the dose to suit patient's individual needs by controlling the volume of the printed drug delivery system has also been demonstrated (7, 17) .
The 3D printed tablets were evaluated for weight variation, dimensions, hardness and friability (Table I ). The friability was reported to be 0% for all the formulation and the crushing strength required to deform or break the tablets was high >350 N. These values clearly demonstrates the superiority of FDM 3D printing over other 3D printed technologies such as extrusion-based (42) and powder-based 3D printing (43, 44) in terms of producing mechanically strong tablets. The generation of ready-to-use tablets at the end of the printing process without any need for finishing or drying step is another instrumental advantage of FDM 3D printing where individualised dosage forms are instantly fabricated on demand.
The disintegration time of 3D printed tablets was found to be <15 min for all tested tablets (Table I ). The applicability of utilising the polymer PVP as an immediate release polymer was also demonstrated through the in vitro dissolution of the drugs from the 3D printed tablets. As elucidated in dissolution data (Fig. 5c ), more than 85% of dipyridamole and theophylline were released within the first 30 min. This confirms the suitability of PVP as a hydrophilic carrier for engineering immediate release 3D printed dosage forms (45) .
In summary, by lowering the temperature of FDM 3D printing process using a hydrophilic polymer, this work reveals the potential of adapting this 3D printing technology to a wider spectrum of drug molecules and to commonly used immediate release dosage forms. Here, the filament-forming process is HME. However, there are a series of other kinds of filament-forming methods such as wet spinning, dry spinning and electrospinning (46, 47) . This work also provides a concept about the combined usage of advanced technologies for creating novel solid dosage forms.
CONCLUSION
By combing FDM with HME, it was possible to fabricate 3D printed tablets with immediate release properties based on PVP and talc as a matrix former and a thermostable filler. The tablets were suitable to make two model drugs and achieved immediate release properties. Tablets showed excellent mechanical properties and acceptable in-batch variability. To the authors' knowledge, this is the first report of employing PVP in FDM 3D printing and a rare example of employing the process to produce immediate release tablets. The reported approach can be employed to fabricate patient-tailored tablets at relatively lower temperature (110°C) and using pharmaceutically approved and solubility enhancing polymer. This work confirms the possibility of expanding the use of FDM 3D printing to a wider range of temperatures for ondemand fabrication of immediate release products. In vitro dissolution profile of theophylline and dipyridamole from PVP based 3D printed tablets using USPII dissolution apparatus.
